Selumetinib: Phase I started

Cancer Research UK began a 2-part, U.K Phase I trial to evaluate the combination of once-daily oral Caprelsa vandetanib and twice-daily oral selumetinib in up to 48 patients. The first part will evaluate escalating doses of 25, 50 and 75 mg selumetinib in combination with Caprelsa in up to 18 patients with solid tumors. The second part will evaluate Caprelsa with the MTD of selumetinib in about 30 non-small cell lung cancer (NSCLC) patients. Cancer Research's Drug Development Office ( DDO) is funding the trial, and AstraZeneca is providing selumetinib and Caprelsa. ...